Analysts predict that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will post ($0.47) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Spring Bank Pharmaceuticals’ earnings. Spring Bank Pharmaceuticals reported earnings per share of ($0.54) during the same quarter last year, which suggests a positive year-over-year growth rate of 13%. The company is expected to issue its next quarterly earnings results on Monday, July 30th.

According to Zacks, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($1.82) per share for the current year, with EPS estimates ranging from ($1.87) to ($1.78). For the next financial year, analysts forecast that the business will post earnings of ($2.42) per share, with EPS estimates ranging from ($2.94) to ($2.03). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Friday, April 27th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.15.

Several equities research analysts recently weighed in on the company. ValuEngine upgraded Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Cantor Fitzgerald set a $32.00 target price on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $30.67.

A number of hedge funds and other institutional investors have recently modified their holdings of SBPH. Wells Fargo & Company MN purchased a new stake in Spring Bank Pharmaceuticals in the fourth quarter valued at approximately $101,000. BlackRock Inc. raised its stake in shares of Spring Bank Pharmaceuticals by 14.8% during the fourth quarter. BlackRock Inc. now owns 32,961 shares of the company’s stock worth $443,000 after purchasing an additional 4,259 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Spring Bank Pharmaceuticals during the fourth quarter worth approximately $172,000. Millennium Management LLC purchased a new stake in shares of Spring Bank Pharmaceuticals during the fourth quarter worth approximately $676,000. Finally, Morse Asset Management Inc raised its stake in shares of Spring Bank Pharmaceuticals by 12.9% during the first quarter. Morse Asset Management Inc now owns 165,775 shares of the company’s stock worth $2,492,000 after purchasing an additional 18,900 shares during the last quarter. Institutional investors own 29.17% of the company’s stock.

SBPH stock traded up $0.12 during trading on Tuesday, hitting $12.56. 13,687 shares of the company’s stock were exchanged, compared to its average volume of 105,852. Spring Bank Pharmaceuticals has a 52-week low of $10.81 and a 52-week high of $18.93.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Featured Article: What does EPS mean?

Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.